<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04950400</url>
  </required_header>
  <id_info>
    <org_study_id>BJCH-NSCLC-IIT</org_study_id>
    <nct_id>NCT04950400</nct_id>
  </id_info>
  <brief_title>A Study of Camrelizumab Combined With Chemotherapy Sequential Camrelizumab Combined With Apatinib Treatment of Advanced NSCLC</brief_title>
  <official_title>A Study of Camrelizumab Combined With Chemotherapy Sequential Camrelizumab Combined With Apatinib For First-line Treatment of Advanced Non-small Cell Lung Cancer (NSCLC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Chest Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Chest Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the safety and efficacy of camrelizumab combined with&#xD;
      chemotherapy in the first-line treatment of advanced in NSCLC patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 7, 2021</start_date>
  <completion_date type="Anticipated">April 4, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 12, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>1 Year</time_frame>
    <description>From the date Into this study to tumor progression or death for any</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival，</measure>
    <time_frame>2 Year</time_frame>
    <description>The time from the beginning of treatment to the death of the subject due to various reasons, calculated by the intended treatment population (ITT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>2 Year</time_frame>
    <description>it is defined as the proportion of patients whose tumors shrink to a predetermined size and maintain a minimum time limit. It includes the cases of CR and PR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate</measure>
    <time_frame>2 Year</time_frame>
    <description>the rate of CR, PR plus SD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>2 Year</time_frame>
    <description>Cr or PR to the first assessment of PD or death from any cause</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Carrelizumab + chemotherapy + apatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carrelizumab + chemotherapy + apatinib</intervention_name>
    <description>Subjects will receive 200 mg of karizumab every three weeks，Pemetrexed 500 mg / m2 was given on the first day of each cycle,Every three weeks was a period of administration,Carboplatin AUC 5 was given on the first day of each cycle and every three weeks was a cycle，Paclitaxel 175 mg / m2 was given on the first day of each cycle, and every three weeks was an administration cycle，with intravenous drip，Apatinib, 250 mg, oral, once a day (PO, QD), every 3 weeks as a cycle.</description>
    <arm_group_label>Carrelizumab + chemotherapy + apatinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. The subjects were 18-70 years old when they signed the informed consent form, and the&#xD;
             age was unlimited for men and women;&#xD;
&#xD;
          2. The late stage (Ⅲ b/ Ⅲ C) and stage IV non-small cell lung cancer (according to AICC&#xD;
             Eighth Edition) which can not be removed by operation and can not be treated with&#xD;
             radical radiotherapy and chemotherapy confirmed by histopathology or cytology;&#xD;
&#xD;
          3. EGFR mutation and alk translocation status were confirmed to be negative at any time&#xD;
             after the initial diagnosis;&#xD;
&#xD;
          4. Subjects had not received systemic systemic chemotherapy for advanced / metastatic&#xD;
             NSCLC. Chemotherapy and / or radiotherapy are allowed to be used as part of new&#xD;
             adjuvant / adjuvant treatment, provided that the treatment has been completed for at&#xD;
             least six months before the diagnosis of advanced or metastatic diseases;&#xD;
&#xD;
          5. ECoG score; 0-1 point;&#xD;
&#xD;
          6. According to RECIST v1.1, subjects must have measurable target lesions through CT or&#xD;
             MRI examination. The imaging assessment of tumor was performed within 28 days before&#xD;
             the first drug use;&#xD;
&#xD;
          7. The main organs function normally, and the test results during screening must meet the&#xD;
             following requirements:&#xD;
&#xD;
        1) The blood routine examination standard should meet the requirements (no blood&#xD;
        transfusion and blood products within 14 days, no correction by G-CSF and other&#xD;
        hematopoietic stimulating factors): A. Hemoglobin (HB) ≥ 90 g/l; B. Neutrophil number (ANC)&#xD;
        ≥ 1.5 × 109/L； C. Platelet count (PLT) ≥ 100 × 109/L； 2) Biochemical examination shall meet&#xD;
        the following standards: A. TBIL was lower than 1.5 upper limit of normal value (ULN); B.&#xD;
        ALT and AST were less than 2.5 ulin, but &lt; 5 uld in liver metastasis; C. The serum&#xD;
        creatinine (CR) &lt; 1.5 ULN or the clearance rate of endogenous creatinine was more than 60ml&#xD;
        / min (Cockcroft Gault formula); D. The results of routine urine test showed that uro was&#xD;
        less than 2+ or 24 hours urinary protein was less than 1G; 8. Men and women of gestational&#xD;
        age must agree to take adequate contraceptive measures throughout the study period and&#xD;
        within 6 months after the treatment.&#xD;
&#xD;
        Sign written informed consent, and it is expected to be in good compliance with the&#xD;
        research plan.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Mixed NSCLC confirmed by histology or cytology, including mixed squamous cell&#xD;
             carcinoma and small cell lung cancer;&#xD;
&#xD;
          2. Previously received anti-PD-1 antibody, anti-PD-L1 antibody, anti-PD-L2 antibody,&#xD;
             anti-CTLA-4 antibody (or any other antibody acting on T cell costimulation or&#xD;
             checkpoint pathway) or any VEGF / VEGFR inhibitor;&#xD;
&#xD;
          3. Patients with active brain metastases (for patients with stable symptoms of brain&#xD;
             metastases after treatment, they can be selected if they remain stable for at least 4&#xD;
             weeks);&#xD;
&#xD;
          4. Imaging evidence of tumor cavity, tumor surrounding or invasion of large blood&#xD;
             vessels. In addition, the degree of proximity of the tumor to the large vessels should&#xD;
             be considered（ The major vessels in the chest include the main pulmonary artery, left&#xD;
             pulmonary artery, right pulmonary artery, four pulmonary veins, superior vena cava,&#xD;
             inferior vena cava and aorta.&#xD;
&#xD;
          5. Immunosuppressive drugs were used within 28 days before the first use of karelizumab,&#xD;
             excluding nasal and inhaled corticosteroids or physiological doses of systemic&#xD;
             steroids (i.e. not more than 10 mg / day prednisolone or other corticosteroids with&#xD;
             the same physiological dose of drugs);&#xD;
&#xD;
          6. Received systemic treatment of Chinese herbal medicine with anti-tumor indications or&#xD;
             immunomodulatory drugs (including thymosin, interferon and interleukin, except for&#xD;
             local use for controlling pleural effusion) within 28 weeks before the first&#xD;
             administration;&#xD;
&#xD;
          7. Inoculate live attenuated vaccine within 30 days of the first administration or within&#xD;
             the expected period of the study（ For the new coronal vaccine vaccinators, whether&#xD;
             they can be selected according to the judgment of the researchers)&#xD;
&#xD;
          8. According to the judgment of the researcher, there is uncontrolled pleural effusion,&#xD;
             pericardial effusion or ascites, or the patient has received serous cavity effusion&#xD;
             drainage for treatment within 4 weeks before treatment.&#xD;
&#xD;
          9. Subjects with severe infection within 1 month before enrollment, including but not&#xD;
             limited to infection complications, bacteremia, severe pneumonia, etc; Subjects with&#xD;
             any active infection, or fever of unknown origin &gt; 38.5 ℃ occurred during screening or&#xD;
             before the first administration;&#xD;
&#xD;
         10. Patients with active autoimmune disease or immunodeficiency, or with the&#xD;
             above-mentioned history, including but not limited to: autoimmune hepatitis,&#xD;
             interstitial pneumonia, uveitis, rheumatoid arthritis, inflammatory bowel disease,&#xD;
             hypophysitis, vasculitis, nephritis, etc.) were not included. The following&#xD;
             exceptions: Patients with a history of autoimmune hypothyroidism but receiving thyroid&#xD;
             hormone replacement therapy were included in the study. After treatment with insulin&#xD;
             regimen, patients with type 1 diabetes who have controlled glycemic control can&#xD;
             participate in this study.&#xD;
&#xD;
         11. Subjects who received systemic therapy such as bronchodilators were not satisfied with&#xD;
             asthma control and could not be included (those who had complete remission of asthma&#xD;
             in childhood and did not need any intervention in adulthood could be included).&#xD;
&#xD;
         12. Human immunodeficiency virus (HIV) infection or acquired immune deficiency syndrome&#xD;
             (AIDS), untreated active hepatitis B, hepatitis C virus (hepatitis C antibody&#xD;
             positive, HCV-RNA higher than the lower limit of analysis method) or co infection of&#xD;
             hepatitis B and hepatitis C; Note: the hepatitis B subjects who met the following&#xD;
             criteria also met the inclusion criteria: HBV viral load must be &lt;1000 copy /ml (200&#xD;
             IU/ml) before the first dose, and the subjects should be treated with anti HBV therapy&#xD;
             during the whole chemotherapy course to avoid virus reactivation. For the subjects&#xD;
             with anti HBC (+), HBsAg (-), anti HBS (-) and HBV viral load (-), preventive anti HBV&#xD;
             treatment is not necessary, but close monitoring of virus reactivation is needed;&#xD;
&#xD;
         13. Subjects have received or plan to receive solid organ or blood system transplantation&#xD;
             (except corneal transplantation) during the study period;&#xD;
&#xD;
         14. Subjects with a history of other malignancies within five years (except for complete&#xD;
             treatment of cervical cancer in situ or basal cell carcinoma or squamous cell&#xD;
             carcinoma or skin cancer);&#xD;
&#xD;
         15. He has hypertension and cannot be well controlled by antihypertensive drugs (systolic&#xD;
             blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg);&#xD;
&#xD;
         16. Clinical symptoms or diseases of heart that can not be well controlled, such as: (1)&#xD;
             heart failure of NYHA grade 2 or above; (2) unstable angina pectoris; (3) myocardial&#xD;
             infarction within one year; (4) clinically significant supraventricular or ventricular&#xD;
             arrhythmia requiring treatment or intervention; (5) QTc &gt; 450ms (male); and; QTc &gt;&#xD;
             470ms (female);&#xD;
&#xD;
         17. Coagulation dysfunction (INR &gt; 2.0, Pt &gt; 16S), bleeding tendency or receiving&#xD;
             thrombolytic or anticoagulant therapy, low-dose aspirin and low molecular weight&#xD;
             heparin are allowed for prophylactic use;&#xD;
&#xD;
         18. Clinically significant hemoptysis or hemoptysis more than half teaspoon (2.5ml) per&#xD;
             day occurred within 2 months before admission; Or significant clinical bleeding&#xD;
             symptoms or clear bleeding tendency, such as gastrointestinal bleeding, hemorrhagic&#xD;
             gastric ulcer, baseline fecal occult blood + + or above, or vasculitis, etc; There&#xD;
             were deep and large ulcers, lesions closely related to big blood vessels and maxilla&#xD;
             and mandible;&#xD;
&#xD;
         19. Arteriovenous thrombosis events occurred in the first 6 months, such as&#xD;
             cerebrovascular accident (including transient ischemic attack, cerebral hemorrhage,&#xD;
             cerebral infarction), deep venous thrombosis and pulmonary embolism, etc; Known&#xD;
             hereditary or acquired bleeding and thrombotic tendency (such as hemophilia,&#xD;
             coagulation dysfunction, thrombocytopenia, etc.);&#xD;
&#xD;
         20. Routine urine examination showed that urine protein was ≥ +, and 24-hour urine protein&#xD;
             was more than 1.0 G;&#xD;
&#xD;
         21. Currently participating in interventional clinical research treatment, or receiving&#xD;
             other experimental drugs or research devices within 4 weeks before the first&#xD;
             administration; Not fully recovered from toxicity and / or complications caused by any&#xD;
             intervention before the first administration (i.e., ≤ grade 1 or baseline, excluding&#xD;
             fatigue or hair loss);&#xD;
&#xD;
         22. Have a clear history of allergy, and may have potential allergy or intolerance to the&#xD;
             test drug and its similar biological agents;&#xD;
&#xD;
         23. Those who have a history of psychotropic drug abuse and can not give up or have mental&#xD;
             disorders; Other conditions that increase the risk associated with participating in&#xD;
             the study or trial drug and, according to the judgment of the investigator, may result&#xD;
             in patients not suitable for inclusion in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ying Hu, doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Chest Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ying Hu, doctor</last_name>
    <phone>01089509304</phone>
    <email>hygzz2004@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>li Ma, doctor</last_name>
    <phone>01089509324</phone>
    <email>silenceli2013@163.com</email>
  </overall_contact_backup>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 29, 2021</study_first_submitted>
  <study_first_submitted_qc>June 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 6, 2021</study_first_posted>
  <last_update_submitted>June 29, 2021</last_update_submitted>
  <last_update_submitted_qc>June 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Chest Hospital</investigator_affiliation>
    <investigator_full_name>Ying Hu</investigator_full_name>
    <investigator_title>Vice Director, Department of oncology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apatinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

